Outcome measures in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by fluctuating multisystem involvement, relapsing-remitting activity, and substantial risk of irreversible organ damage. Standardized disease activity indices have facilitated clinical trials and research, yet integration into clinical practice has not occurred for most practitioners. Traditional instruments, including SLE Disease Activity Index, British Isles Lupus Assessment Group (BILAG), Systemic Lupus Activity Measure, and European Consensus Lupus Activity Measurement, provide objective measures of disease activity, whereas dichotomous composite indices, such as SRI or BILAG-based Composite Lupus Assessment, distinguish between response and nonresponse to a therapeutic intervention. Emerging tools, such as the SLE Disease Activity Score, offer continuous, weighted scoring that captures subtle changes in activity and aligns with treat-to-target frameworks, including Lupus Low Disease Activity State and Definition of Remission in SLE criteria. Organ-specific measures, patient-reported outcomes, and damage accrual indices complement global assessments but are rarely integrated into a unified, actionable metric. This review synthesizes the evolution of SLE outcome measures, evaluates their strengths and limitations, and discusses future directions - including biomarker integration, imaging, and digital health innovations - toward developing comprehensive, clinically feasible, multidimensional assessment strategies.